This phase III trial will assess an adjuvant immunotherapy in children and adults who have completed surgery for Stage IIB/C melanoma and have a high risk of their cancer coming back.
This trial is treating patients with melanoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has not spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy With Nivolumab Versus Placebo After Complete Resection of Stage IIB/C Melanoma
Bristol-Myers Squibb (BMS)
Eligible patients will be randomised to receive nivolumab or a placebo-equivalent on specified days in a treatment cycle.
Recruiting Hospitals Read More